Compare · DXCM vs RMED
DXCM vs RMED
Side-by-side comparison of DexCom Inc. (DXCM) and Ra Medical Systems Inc. (RMED): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and RMED operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $29.57B, about 4392.5x RMED ($6.7M).
- DXCM has hit the wire 26 times in the past 4 weeks while RMED has been quiet.
- DXCM has more recent analyst coverage (25 ratings vs 1 for RMED).
- Company
- DexCom Inc.
- Ra Medical Systems Inc.
- Price
- $76.59+5.15%
- $0.57+4.03%
- Market cap
- $29.57B
- $6.7M
- 1M return
- +25.71%
- -
- 1Y return
- -10.56%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2005
- 2018
- News (4w)
- 26
- 0
- Recent ratings
- 25
- 1
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Ra Medical Systems Inc.
Ra Medical Systems, Inc., a commercial-stage medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular and dermatological immune-mediated inflammatory diseases. The company offers DABRA (destruction of arteriosclerotic blockages by laser radiation ablation), a minimally-invasive excimer laser and single-use catheter system that is used by physicians in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease. It also provides Pharos, an excimer laser device that emits highly concentrated ultraviolet light and is used as a tool in the treatment of dermatological skin disorders. The company sells its products primarily through its direct sales force in the United States. Ra Medical Systems, Inc. was incorporated in 2002 and is headquartered in Carlsbad, California.
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
Latest RMED
- SEC Form SC 13G filed by Ra Medical Systems Inc.
- Ra Medical Systems Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities
- Jenkins David A bought $9,786 worth of shares (19,056 units at $0.51), increasing direct ownership by 6% to 329,856 units (SEC Form 4)
- Jenkins David A bought $7,086 worth of shares (16,940 units at $0.42), increasing direct ownership by 6% to 310,800 units (SEC Form 4)
- Jenkins David A bought $6,323 worth of shares (16,263 units at $0.39), increasing direct ownership by 6% to 293,860 units (SEC Form 4)
- SEC Form SC 13D/A filed by Ra Medical Systems Inc. (Amendment)
- Ra Medical Systems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 4 filed by Thomassen Margrit
- SEC Form 4 filed by Francis, John P.
- New insider Francis, John P. claimed ownership of 2,611 shares (SEC Form 3)